IQV IQVIA Holdings Inc. stock chart & analysis
Conviction 52HealthcareScan · Fri, Nov 6, 2026IQVIA Holdings Inc. (IQV) closed at $271.83 (+2.62%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 54, RS Rating 90, -4.5% from its 52-week high, +20.5% year to date. Sector: Healthcare · Services-Commercial Physical & Biological Research.
Financials as of Wed, Sep 30, 2026 · quarterly.
IQV technical analysis
Trend
IQV is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 2.0% above the 50-day ($266.45) and 29.3% above the 200-day ($210.16). ADX(14) at 22 points to a moderate trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 54, in the bullish half of its range. MACD crossed below its signal line 5 sessions ago. Its RS Rating of 90 puts its weighted 12-month performance ahead of about 90% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $377.3M a day on average. ATR(14) is $9.32, 3.4% of price — its typical daily range. On-balance volume is trending up.
Key levels
The chart pattern's support is $252.47 and its resistance $283.74. The 52-week range is $154.50 to $284.50; price is 4.5% below the high and 75.9% above the low. The VWAP anchored at the 52-week high is $268.82, below price.
Performance
IQV returned +1.7% (1 week), +5.0% (1 month), +12.3% (3 months), +52.0% (6 months), +29.3% (1 year), +20.5% (year to date).
About IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Services-Commercial Physical & Biological Research · Listed 2013 · 93,000 employees
Congress activity
Disclosed STOCK Act trades in IQV · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Kevin Hern house · R · OK · traded 2026-09-14 | Sell | $15K–$50K | 2026-09-14 | 2026-09-25 | |
Kevin Hern house · R · OK · traded 2026-09-08 | Sell | $1K–$15K | 2026-09-08 | 2026-09-25 | |
Kevin Hern house · R · OK · traded 2026-09-03 | Sell | $1K–$15K | 2026-09-03 | 2026-09-25 | |
 Markwayne Mullin senate · traded 2025-12-29 | Buy | $15K–$50K | 2025-12-29 | 2026-01-16 | |
 John Boozman senate · R · AR · traded 2025-10-02 | Sell | $1K–$15K | 2025-10-02 | 2025-11-15 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Sell | $1K–$15K | 2025-05-15 | 2025-05-31 | |
Rob Bresnahan house · PA · traded 2025-04-08 | Buy | $15K–$50K | 2025-04-08 | 2025-05-08 | |
Rob Bresnahan house · PA · traded 2025-02-25 | Sell | $1K–$15K | 2025-02-25 | 2025-03-27 | |
Markwayne Mullin senate · traded 2025-02-13 | Buy | $15K–$50K | 2025-02-13 | 2025-02-27 | |
Markwayne Mullin senate · traded 2024-08-20 | Buy | $15K–$50K | 2024-08-20 | 2024-09-19 |
Insider activity
SEC Form 4 transactions in IQV
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
DANHAKL JOHN G Director · Deferred Shares · 2026-07-14 | Grant | 160 | $33K | 2026-07-14 | 2026-07-16 |
Fasano Jim Director · Deferred Shares · 2026-07-14 | Grant | 195 | $41K | 2026-07-14 | 2026-07-16 |
GOGGINS COLLEEN A Director · Deferred Shares · 2026-07-14 | Grant | 183 | $38K | 2026-07-14 | 2026-07-16 |
Wims Morris Leslie Director · Deferred Shares · 2026-07-14 | Grant | 148 | $31K | 2026-07-14 | 2026-07-16 |
GOGGINS COLLEEN A Director · Deferred Shares · 2026-05-07 | Grant | 214 | $38K | 2026-05-07 | 2026-05-11 |
Fasano Jim Director · Deferred Shares · 2026-05-07 | Grant | 228 | $41K | 2026-05-07 | 2026-05-11 |
DANHAKL JOHN G Director · Deferred Shares · 2026-05-07 | Grant | 185 | $33K | 2026-05-07 | 2026-05-11 |
Wims Morris Leslie Director · Deferred Shares · 2026-05-07 | Grant | 171 | $31K | 2026-05-07 | 2026-05-11 |
GOGGINS COLLEEN A Director · Common Stock · 2026-04-23 | Grant | 1.57K | $0 | 2026-04-23 | 2026-04-27 |
LEONARD JOHN M Director · Common Stock · 2026-04-23 | Grant | 1.57K | $0 | 2026-04-23 | 2026-04-27 |
SEC filings
EDGAR filings in IQV · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.